Psychedelic Finance
Psychedelic Finance is a private digital media platform that provides news, spotlight interviews, and a company database serving individual investors in the psychedelic medicine industry, anchored by a free newsletter with 50,000+ subscribers.
- Company typePrivate
- Founded-
- HeadquartersVictoria, Canada
- Headcount11–50
- GTM typeB2C
- OfferingDigital Commerce or Content
What Psychedelic Finance does
Psychedelic Finance is a private digital media and content platform serving investors in the psychedelic medicine industry. The company operates a website (psychedelicfinance.com) that publishes news articles, spotlight interviews with scientists and executives, and a company database covering 100+ psychedelic and mental health companies. Its primary audience acquisition and retention channel is a free email newsletter with 50,000+ subscribers, distributed alongside active social media accounts on Twitter (@psych_fin) and Instagram (@psychedelic.finance), and an RSS feed. The platform is based in Victoria, Canada, and claims a global audience, with no geographic restrictions stated on its content.
The company's core product is editorial — not SaaS — and its underlying technology stack is a standard Webflow CMS with no proprietary technical components, no AI/ML capabilities, no APIs, and no mobile app. Its disclosed value proposition is to help investors discover, understand, and stay up to date with the psychedelic business landscape, addressing the information fragmentation problem that exists in an emerging industry sector.
Psychedelic Finance's business model is freemium. The newsletter and core content are provided free of charge, and no paid tiers, advertising rates, or sponsorship programs are publicly disclosed. The company has 11-50 employees, no disclosed funding rounds, no parent company, no institutional investors, and no management team information in the source materials. The partnerships listed in the source data actually describe partnerships among psychedelic companies that Psychedelic Finance covers in its news (e.g., Beckley Psytech/Ksana Health, Cybin/Small Pharma, MAPS/Cohen Foundation), not partnerships of Psychedelic Finance itself. The company is operating but shows limited disclosed commercial traction beyond its community size.
Psychedelic Finance firmographics
Firmographics- Name
- Psychedelic Finance
- Legal name
- Psychedelic Finance
- Website
- https://psychedelicfinance.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Psychedelic Finance is a private digital media platform that provides news, spotlight interviews, and a company database serving individual investors in the psychedelic medicine industry, anchored by a free newsletter with 50,000+ subscribers.
- Ownership category
- akta.pro rank
Psychedelic Finance industry classification
Industry- Product category
- Financial News Media
- NAICS
- Information (51)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Prediction Markets & Information Finance (FSADAMAJ)
Keywords
Where Psychedelic Finance is headquartered
LocationHeadquarters
- HQ city
- Victoria
- HQ country
- Canada
- HQ region
- North America
Markets served
Psychedelic Finance business model
Business model- GTM type
- B2C
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Newsletter Subscriptions: Free newsletter providing investors with psychedelic industry news, company features, and market updates.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | — | Free newsletter subscription |
Distribution channels1 record
Marketing channels6 records
Psychedelic Finance product offering
Product offeringCore offering
Psychedelic Finance operates a free digital media platform that delivers news, insights, and market intelligence on the financial and business aspects of the psychedelic industry. Its core offerings include a free investor-focused newsletter, a company database covering 100+ psychedelic and mental health companies, news articles, and exclusive spotlight interviews with industry scientists, leaders, and executives.
Product overview
Psychedelic Finance is a news and company database platform serving the psychedelic industry. The platform provides a company directory featuring profiles of psychedelic and mental health companies, publishes news articles and industry updates, and offers spotlight interviews with scientists and executives in the field. The platform also maintains a newsletter subscription service and a community of over 50,000 members. It does not offer a traditional SaaS product but rather serves as an informational and editorial resource for investors and industry participants.
Differentiator
Problem solved
Functional benefit
Products and services
- Psychedelic Finance Newsletter
Quantifiable outcome
- 50,000+ community members receiving free newsletter
Companies that use Psychedelic Finance
Customer profileSegments1 record
Ideal customer profiles1 record
Psychedelic Finance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Psychedelic Finance partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- FluencecoreCybin announced agreement with Fluence to support scaling of EMBARK Training for CYB003 Phase 3 Trial in Major Depressive Disorder.
- Johns Hopkins UniversitycoreClearmind Medicine announced clinical research collaboration with Johns Hopkins University to evaluate CMND-100 in patients with Alcohol Use Disorder.
- MAPScoreNuminus announced partnership with MAPS to support therapist psychedelic experiential training, aligning business initiatives to prepare for future approval of MDMA-assisted therapy.
- University of ExetercoreAwakn Life Sciences signed collaboration agreement with University of Exeter for Phase III trial exploring ketamine-assisted therapy to treat Severe AUD. Professor Celia Morgan will lead the trial with Awakn contributing GBP £800,000.
- Nova Mentis Life SciencecoreKGK Science (subsidiary of Wellbeing Digital Sciences) partnered with Nova Mentis to conduct Phase IIA clinical trial testing psilocybin for fragile X syndrome at KGK facility in London, Ontario.
- King's College HospitalcoreBeckley Psytech's Phase IIa study of BPL-003 for Treatment Resistant Depression taking place at King's College Hospital and Hammersmith Medicines Research, with Dr. James Rucker as Principal Investigator.
- Hammersmith Medicines ResearchcoreBeckley Psytech's Phase IIa study of BPL-003 for Treatment Resistant Depression taking place at King's College Hospital and Hammersmith Medicines Research.
- Eleusis Therapeutics LimitedcoreBeckley Psytech acquired Eleusis Therapeutics Limited in an all-equity transaction, adding ELE-101 (IV formulation of psilocin) to the pipeline and receiving full developmental and commercial rights for the company's assets.
Scale indicators1 record
Recent moves4 records
Expansion highlights3 records
Psychedelic Finance competitors and assessment
Company assessmentDirect peers
- Psychedelic Science Review: Psychedelic industry news and information platform providing news, research summaries, and company coverage. Closest topical peer covering the psychedelic industry, though less investor-focused than Psychedelic Finance.
- The Block: Crypto-focused financial news and research platform providing news, market intelligence, and institutional-grade data. Similar niche-focused approach of providing deep financial information for an emerging-asset investor audience.
- Endpoints News: Biotech/pharma industry news outlet covering drug development, clinical trials, financings, and M&A for industry professionals. Comparable in providing daily news to investors/operators in a life-sciences-adjacent vertical.
- Business of Cannabis: Cannabis industry financial and business news outlet targeting investors and operators with market intelligence and company coverage. Mirrors Psychedelic Finance's model of covering an emerging, regulated therapeutic industry for investor audiences.
- Third Wave: Psychedelic-focused media platform providing news, education, and community content. Covers the same psychedelic industry vertical but with a more consumer/education orientation rather than pure investor focus.
- MJBizDaily: Leading business news and resource platform for the cannabis industry, covering financial, regulatory, and operational developments. Closest analog in terms of vertical-specific financial media serving a single emerging industry.
- CoinDesk: Leading crypto industry news and information platform serving investors with news, research, and data products. Same business model as Psychedelic Finance but applied to the digital assets sector, including paid subscriptions and events.
- Green Market Report: Cannabis-focused financial news platform serving investors in the cannabis industry with news, company coverage, and market intelligence. Highly analogous business model to Psychedelic Finance but applied to the more mature cannabis sector.
Emerging players
- Decrypt: Crypto industry news and education platform covering digital assets, DeFi, and Web3 with broad consumer-investor focus. Similar model of vertical media targeting retail-investor audiences in an emerging asset class.
Broad incumbents
- Fierce Biotech: Established biotech industry news brand covering drug development and company news, with broader scope and larger audience than Psychedelic Finance. Comparable as a life-sciences vertical news destination but with much wider coverage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Psychedelic Finance social profiles
Digital presencePsychedelic Finance financial estimates
Financial estimateRevenue estimate
Valuation estimate
Psychedelic Finance leadership team
Management profileNumber of profiles
Psychedelic Finance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Psychedelic Finance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Psychedelic Finance
What does Psychedelic Finance do?
Psychedelic Finance operates a free digital media platform that delivers news, insights, and market intelligence on the financial and business aspects of the psychedelic industry. Its core offerings include a free investor-focused newsletter, a company database covering 100+ psychedelic and mental health companies, news articles, and exclusive spotlight interviews with industry scientists, leaders, and executives.
Is Psychedelic Finance a public or private company?
Psychedelic Finance is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Psychedelic Finance founded?
Psychedelic Finance was founded in -1. It employs 11 to 50 people.
Where is Psychedelic Finance based?
Psychedelic Finance is headquartered in Victoria, Canada, in the North America region.
How does Psychedelic Finance make money?
One revenue line is on record: newsletter Subscriptions.
Who are Psychedelic Finance's main competitors?
Direct peers on record are Psychedelic Science Review, The Block, Endpoints News, Business of Cannabis, Third Wave, MJBizDaily, CoinDesk and Green Market Report. Decrypt is listed as an emerging player. Fierce Biotech is listed as a broad incumbent.
Does Psychedelic Finance have an API?
No public API is recorded for Psychedelic Finance.
What industry is Psychedelic Finance in?
Psychedelic Finance's product category is Financial News Media. Its primary akta.pro industry code is FSADAMAJ, Prediction Markets & Information Finance. Its NAICS code is 51 and its SIC code is 6282.